Henriette Jodal. Photo: Stian Strøm Arnesen

One of the major concerns of cancer screening is interval cancers, which are cancers arising after a negative screening test. These cancers have been believed to be especially aggressive and have a poor prognosis. A new study shows that they are not.



A paper published today in BMJ shows no effect of sigmoidoscopy screening in women aged 60 years and older. This new finding will have implications for a future Norwegian colorectal cancer screening program, where sigmoidoscopy is one of the recommended screening methods.  

Screenshot of newspaper Dagens Næringsliv

In an Op-Ed published in the Norwegian daily newspaper Dagens Næringsliv (DN) on November 29, researchers from the Clinical Effectiveness Research group criticize Norwegian private hospital Aleris' offer to women for mammography screening. Aleris actively offers mammography to women outside the recommended screening age and with shorter intervals, a service which is associated with more harm than benefit. The authors suspect Aleris of creating health anxiety in order to maximize profit. 

This week's issue of the Journal of the Norwegian Medical Association is presenting a portrait interview of Mette Kalager, leader of the Clinical Effectiveness Group. Kalager reveals insights about early career struggles, recent acknowledgements and aims for the future.

The Clinical Effectiveness Group is in the final round to be awarded status as a new Norwegian Centre of Excellence (SFF) 2016. In the event of an SFF-award the group will start up the Norwegian Institute of Cancer screening Evidence and Research (NICER). Watch the film about NICER!

The Clinical Effectiveness Research Group at the University of Oslo is publishing papers on clinical trials and observational research in leading medical journals. Topics of publication include cancer screening, with particular emphasis on breast cancer and colorectal cancer, endoscopy and epidemiologic methodology. 

The University Hospital of North Norway (UNN) and the University of Tromsø (UiT) are now participants  in what is described as the world's largest research project on bowel cancer EPoS according to the newspaper iTromsø.